US Patent 8017621 Inhibitors of the mutant form of kit
Patent 8017621 was granted and assigned to Novartis on September, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 21 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+287 characters)
Article
Patent abstract
The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT selected form midostaurin, vatalanib and compound A is administered.
Edits on 20 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Doriano Fabbro0
Elisabeth Buchdunger0
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08017621 Inhibitors of the mutant form of kit US Patent 8017621 Inhibitors of the mutant form of kit
Infobox
Patent Number
080176210
Patent Number
80176210
Edits on 23 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
080176210
Date of Patent
September 13, 2011
0Patent Application Number
105795860
Date Filed
November 17, 2004
0Patent Primary Examiner
Edits on 13 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08017621 Inhibitors of the mutant form of kit
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08017621
Date of patent
September 13, 2011
Patent application number
10579586
Date Filed
November 17, 2004
Patent primary examiner
Find more entities like US Patent 8017621 Inhibitors of the mutant form of kit
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
